US-based Avara Pharmaceutical Services has signed an asset purchase agreement to acquire Novartis Technical Operations’ sterile manufacturing facility for injectable medicines in Quebec, Canada.

The deal also covers the nearby Sandoz Development Center situated on the Sandoz Canada campus in Boucherville.

Said to be the biggest injectables production facility in Canada, the site supplies multiple drugs across the country’s healthcare system, primarily hospitals.

Avara is planning to invest in the facility and work on business development opportunities in order to optimise the site’s utilisation and boost its customer base.

The company noted that employees may not be impacted by the move.

Avara Pharmaceutical Services chairman and CEO Timothy Tyson said: “This acquisition represents our first entry into the Canadian market and further expands our sterile processing capability, which is in very high demand.

“This further expands our sterile processing capability, which is in very high demand.”

“It comes with a world-class development centre and a dedicated team of experts that will support us in delivering high-quality pharmaceuticals that meet or exceed customer expectations and regulatory requirements.”

As part of the deal, the partners have revealed plans for a long-term supply contract aimed at uninterrupted product supply.

Financial details of the agreement have not been disclosed. The acquisition is subject to closing conditions and expected to be finalised over the coming months.

Last year, Avara purchased Pfizer’s sterile plant located in Liscate, Italy, along with a solid dose manufacturing site in Aiken, South Carolina, US, from GlaxoSmithKline.

The latest deal with Novartis brings the number of manufacturing and development sites operated by Avara to a total of ten, with two in Canada, three in the US, and one each in the UK, Ireland, France, Italy, and Puerto Rico.